Salvato in:
Dettagli Bibliografici
Autori principali: Rebecca von Dannecker, Lilia Maria Lima de Oliveira, Izadora Lapenda, Luiza Pinto, Sarah Soares Amorim, Eduarda Pandia, Michele Kreuz, Ana Julia Marques Bluhm, Matheus de Melo Lobo
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:https://onlinelibrary.wiley.com/doi/10.1111/ijd.17841
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867015706959151104
author Rebecca von Dannecker
Lilia Maria Lima de Oliveira
Izadora Lapenda
Luiza Pinto
Sarah Soares Amorim
Eduarda Pandia
Michele Kreuz
Ana Julia Marques Bluhm
Matheus de Melo Lobo
author_facet Rebecca von Dannecker
Lilia Maria Lima de Oliveira
Izadora Lapenda
Luiza Pinto
Sarah Soares Amorim
Eduarda Pandia
Michele Kreuz
Ana Julia Marques Bluhm
Matheus de Melo Lobo
Rebecca von Dannecker
Lilia Maria Lima de Oliveira
Izadora Lapenda
Luiza Pinto
Sarah Soares Amorim
Eduarda Pandia
Michele Kreuz
Ana Julia Marques Bluhm
Matheus de Melo Lobo
collection Wiley Open Access
contents Clinical Outcomes and Prognosis in Atypical Fibroxanthoma: A Systematic Review and Meta‐Analysis Rebecca von Dannecker Lilia Maria Lima de Oliveira Izadora Lapenda Luiza Pinto Sarah Soares Amorim Eduarda Pandia Michele Kreuz Ana Julia Marques Bluhm Matheus de Melo Lobo International Journal of Dermatology ABSTRACT Atypical fibroxanthoma (AFX) is a rare dermal spindle‐cell tumor characterized by a generally benign clinical course. Despite recent advances, there are still challenges regarding its accurate diagnosis, prognostic indicators, and optimal management strategies. This systematic review and meta‐analysis aims to evaluate recurrence rates, identify prognostic factors, and provide evidence‐based insights for managing AFX. We systematically searched the PubMed, Embase, Web of Science, and Cochrane databases following PRISMA guidelines (PROSPERO: CRD42024507089). Observational studies published from 2002 to 2024 that confirmed AFX through histopathology and immunohistochemistry were included. Recurrence rates and prognostic factors were analyzed using a random‐effects model with inverse‐variance weighting. Sensitivity analysis assessed heterogeneity, while publication bias was evaluated via funnel plots and Egger's test. Eight studies involving 1366 patients were analyzed. Patients were predominantly elderly males (78.9%), with an average age of 76.9 years, and lesions mostly in the head and neck region (89%), measuring about 14.9 mm in diameter. The pooled local recurrence rate was 4.73% [95% confidence interval (CI): 2.24–9.73%; I 2  = 62.1%], while the metastasis rate was 0.59%, and disease‐specific mortality was 0%. Strict adherence to standardized diagnostic criteria results in low recurrence rates in AFX, reinforcing its predominantly benign clinical behavior. Therefore, we highlight the importance of maintaining strict diagnostic standards for AFX to ensure accurate patient prognosis. 10.1111/ijd.17841 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/ijd.17841
format Artículo Open Access
id wiley_oa_10_1111_ijd_17841
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Clinical Outcomes and Prognosis in Atypical Fibroxanthoma: A Systematic Review and Meta‐Analysis
Rebecca von Dannecker
Lilia Maria Lima de Oliveira
Izadora Lapenda
Luiza Pinto
Sarah Soares Amorim
Eduarda Pandia
Michele Kreuz
Ana Julia Marques Bluhm
Matheus de Melo Lobo
International Journal of Dermatology
Clinical Outcomes and Prognosis in Atypical Fibroxanthoma: A Systematic Review and Meta‐Analysis Rebecca von Dannecker Lilia Maria Lima de Oliveira Izadora Lapenda Luiza Pinto Sarah Soares Amorim Eduarda Pandia Michele Kreuz Ana Julia Marques Bluhm Matheus de Melo Lobo International Journal of Dermatology ABSTRACT Atypical fibroxanthoma (AFX) is a rare dermal spindle‐cell tumor characterized by a generally benign clinical course. Despite recent advances, there are still challenges regarding its accurate diagnosis, prognostic indicators, and optimal management strategies. This systematic review and meta‐analysis aims to evaluate recurrence rates, identify prognostic factors, and provide evidence‐based insights for managing AFX. We systematically searched the PubMed, Embase, Web of Science, and Cochrane databases following PRISMA guidelines (PROSPERO: CRD42024507089). Observational studies published from 2002 to 2024 that confirmed AFX through histopathology and immunohistochemistry were included. Recurrence rates and prognostic factors were analyzed using a random‐effects model with inverse‐variance weighting. Sensitivity analysis assessed heterogeneity, while publication bias was evaluated via funnel plots and Egger's test. Eight studies involving 1366 patients were analyzed. Patients were predominantly elderly males (78.9%), with an average age of 76.9 years, and lesions mostly in the head and neck region (89%), measuring about 14.9 mm in diameter. The pooled local recurrence rate was 4.73% [95% confidence interval (CI): 2.24–9.73%; I 2  = 62.1%], while the metastasis rate was 0.59%, and disease‐specific mortality was 0%. Strict adherence to standardized diagnostic criteria results in low recurrence rates in AFX, reinforcing its predominantly benign clinical behavior. Therefore, we highlight the importance of maintaining strict diagnostic standards for AFX to ensure accurate patient prognosis. 10.1111/ijd.17841 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Clinical Outcomes and Prognosis in Atypical Fibroxanthoma: A Systematic Review and Meta‐Analysis
topic International Journal of Dermatology
url https://onlinelibrary.wiley.com/doi/10.1111/ijd.17841